ArticleEuropean heart journal. Case reports2026
Real-world presentation of myocardial bridging in the cath-lab: a case series.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: myocardial bridging (MB), an intramyocardial course of an epicardial coronary segment, is common yet frequently underrecognized on angiography, and can provoke ischaemia via multiple, overlapping mechanisms. High-resolution optical coherence tomography (OCT), paired with targeted physiological testing, may improve Case summary: we report eight contemporary, catheterization-lab cases illustrating the heterogeneous anatomy, physiology, and clinical expression of MB. Clinical presentation ranged from myocardial infarction with/without ST-elevation to acute heart failure. OCT consistently revealed recurrent morphologies, namely: homogeneous 'media-like' bands abutting the adventitia, sharp-bordered fusiform or 'moon-shaped' perivascular areas, or dynamic and asymmetric vessel distortion tracking with the muscular cuff. Management was individualized: (i) medical therapy with β-blockers when ischaemia was attributable to MB alone; (ii) OCT-guided percutaneous coronary intervention for adjacent atherosclerotic disease with precise landing-zone selection; (iii) in one case, integrated functional assessment, including dobutamine and acetylcholine testing, to unmask epicardial haemodynamic significance, microvascular dysfunction, and vasospasm, informing agent selection. Clinical outcomes were favourable, with symptom resolution and preserved or improved LV function over follow-up intervals up to 2 years. Discussion: MB modulates coronary flow, atherogenesis, and procedural risk. An integrated approach that combines structural definition with intravascular imaging, stress state physiology, and vasoreactivity testing is essential to clarify mechanisms, tailor therapy, and mitigate the pitfalls of stenting near tunnelled segments. This real-world series offers a pragmatic roadmap for decoding MB related ischaemia and for translating concordance between imaging and physiology into optimized, individualized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.